Addressing Antimicrobial Resistance (AMR)—The Growing Threat
Antimicrobial resistance is making once-treatable infections deadly again, threatening everything from routine surgeries to cancer care. Without urgent intervention, AMR could cause 39 million deaths by 2050 and destabilize global economies. This crisis is a failure of innovation, access, and coordination—and it demands bold, collective, decentralised action.
The MicroDAO Vision
Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi, or parasites evolve to resist the drugs—like antibiotics and antivirals—meant to kill them. As a result, infections become harder, and sometimes impossible, to treat, leading to longer illnesses, higher costs, and more deaths. Even minor infections or routine surgeries can become life-threatening without effective antimicrobials. AMR affects humans, animals, and the environment, making it a complex global issue driven largely by the overuse and misuse of these drugs across health, agriculture, and ecosystems.
Why does solving AMR matter?
Addressing antimicrobial resistance is essential to protecting the foundation of modern medicine. Without effective antimicrobials, routine infections, minor injuries, and surgeries could once again become deadly, and treatments like cancer care, organ transplants, and childbirth would carry far greater risk. AMR also threatens food security, animal health, the environment, and global economies—disproportionately impacting low- and middle-income countries. Tackling it is about saving lives, preserving medical progress, and securing a healthier, more resilient future for all.
How microDAO plans to address AMR
MicroDAO is building a decentralised, global community of researchers, clinicians, innovators, and policymakers to tackle AMR. At the core of this model is a curated marketplace of high-quality datasets, AI models, and analysis tools designed to accelerate research and R&D pipelines—by identifying promising targets, refining discovery processes, and informing clinical applications.
Through this infrastructure, MicroDAO creates a sustainable funding cycle that supports breakthrough research in antimicrobials, vaccines, and diagnostics, reinvesting value back into the ecosystem with every success.
.svg)
3.svg)
Launch & Revenue Generation
MicroDAO launches a digital token and a platform that offers valuable tools and resources to the scientific community. Revenue from token sales and platform use flows directly into a research funding pool.
Community-Driven Funding Allocation
Funds are allocated to high-potential research projects through community voting, directing support toward innovative solutions in AMR, vaccine, and diagnostic development.
Development & IP Creation
Selected projects develop new treatments and technologies, producing commercially valuable intellectual property (IP-NFTs) in the process.
Reinvestment Through Commercial Success
Revenue from successful products is returned to the funding pool, fueling a continuous, self-sustaining cycle of research, development, and reinvestment.
Roadmap
The MicroDAO roadmap outlines a clear path from infrastructure buildout to ecosystem-wide impact. Each milestone reflects our commitment to decentralised governance, sustainable funding, and accelerating innovation in the fight against antimicrobial resistance—from launching core platforms and research tools to scaling targeted therapies and community-driven funding.
Q2 2025
Laying the Foundation for Scaled Impact
MicroDAO is entering a pivotal stage of growth with the launch of a Bio.xyz partnership to accelerate market reach, a full rebrand and new website, and the release of both a strategic litepaper and an updated whitepaper. These milestones will clarify our vision, strengthen our identity, and provide a detailed roadmap for what's ahead.
Q3 2025
Activating Core Infrastructure
This phase marks the launch of the MicroDAO Marketplace, connecting contributors across the AMR ecosystem through a shared platform for tools, data, and collaboration. Alongside it, the alpha release of the Economic Impact Calculator will help quantify the true cost of AMR, providing powerful data to guide funding and policy decisions.
Q4 2025
Expanding Access to Targeted Solutions
The launch of the Pathogen Solution Marketplace will create a direct channel between AMR solution developers and targeted funders, accelerating the path from research to real-world therapies and addressing the market failures that have held back critical innovation.
Q1 2026
Activating Governance and Funding
This phase introduces the MICRO token generation event, activating DAO-based governance and community participation. Alongside it, MicroDAO will launch two major funding programs: one to support Marketplace developers and another to back breakthrough AMR research, establishing the foundation for a robust, decentralised innovation ecosystem.
Q2 2026
Expanding Biomedical Impact
MicroDAO will broaden its funding scope to include vaccine and diagnostic development, extending support beyond tools and data toward full-spectrum solutions that address the most urgent gaps in AMR innovation.
Reading & Resources
Discover DeSci
Web3 and decentralised science are reshaping how research gets funded, shared, and rewarded. Learn how it works, and why it matters.
